DEE ANN OMATSU: Open Payments
NPI 1851523211 · HONOLULU, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,222 in 19 payments from 13 companies in 2025. Trend: 2023 $1,314 · 2024 $1,426 · 2025 $2,222
Food & beverage: $2,064Education: $158
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $501 |
| Janssen Biotech, Inc. | 2 | $297 |
| E.R. Squibb & Sons, L.L.C. | 2 | $254 |
| SEAGEN INC. | 2 | $158 |
| Syndax Pharmaceuticals, Inc. | 1 | $150 |
| Daiichi Sankyo Inc. | 1 | $144 |
| GENZYME CORPORATION | 1 | $135 |
| BTG International Inc. | 1 | $125 |
| PharmaEssentia USA Corporation | 1 | $122 |
| Incyte Corporation | 1 | $120 |
Products named: RYBREVANT, BREYANZI, REVUFORJ, SARCLISA, ENHERTU, VORAXAZE, BESREMI, Jakafi.
Industry payments across HI — which companies pay providers there.
